Stifel Nicolaus Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its target price raised by stock analysts at Stifel Nicolaus from $300.00 to $345.00 in a report released on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. Stifel Nicolaus' price objective points to a potential upside of 41.63% from the company's current price.

A number of other research firms have also recently weighed in on ALNY. HC Wainwright upped their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a "buy" rating in a research report on Monday, February 24th. Sanford C. Bernstein cut their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. Bank of America raised their price objective on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, March 21st. Finally, JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $316.25.

Remove Ads

Alnylam Pharmaceuticals Stock Down 7.1 %

NASDAQ:ALNY traded down $18.57 during mid-day trading on Monday, hitting $243.59. The company had a trading volume of 735,603 shares, compared to its average volume of 837,082. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a market capitalization of $31.69 billion, a price-to-earnings ratio of -112.22 and a beta of 0.30. The business has a fifty day simple moving average of $259.89 and a 200-day simple moving average of $260.57.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the business's stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company's stock, valued at $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 in the last quarter. Company insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP boosted its position in shares of Alnylam Pharmaceuticals by 1,754.5% during the 3rd quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 193 shares in the last quarter. Bridgewater Associates LP acquired a new stake in Alnylam Pharmaceuticals during the third quarter valued at approximately $551,000. Captrust Financial Advisors boosted its holdings in Alnylam Pharmaceuticals by 34.4% during the third quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company's stock worth $1,329,000 after buying an additional 1,237 shares in the last quarter. True Wealth Design LLC grew its position in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 153 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $4,539,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.